A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

Summary

CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.

Timeline

Start

2006-11

Primary completion

—

Completion

2008-02

Drugs

Indications